Treatment with anti-ErbB2 antibodies

CAFC
  • US 8,425,908 B2
  • Filed: 07/18/2011
  • Issued: 04/23/2013
  • Est. Priority Date: 12/12/1997
  • Status: Expired due to Fees
First Claim
Patent Images

1. A method for the treatment of a human patient with gastric cancer characterized by overexpression of ErbB2 receptor, comprising administering an effective amount of a combination of an anti-ErbB2 antibody, or an antigen-binding fragment thereof, and a chemotherapeutic agent, to the human patient, wherein the chemotherapeutic agent is capecitabine or 5-fluorouracil, wherein the attending physician is provided with instructions including a warning that the treatment is not to be performed in combination with an anthracycline derivative and wherein said antibody binds to epitope 4D5 within the ErbB2 extracellular domain sequence.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×